A reliable risk score for stage IV esophagogastric cancer.

摘要: Abstract Background The role of surgery for patients with metastatic esophagogastric adenocarcinoma (EGC) is not defined. purpose this study was to define selection criteria who may benefit from resection following systemic chemotherapy. Methods From 1987 2007, 160 presenting synchronous EGC (cT3/4 cNany cM0/1 finally pM1) were treated chemotherapy followed by the primary tumor and metastases. Clinical histopathological data, site number metastases analyzed. A prognostic score established validated in a second cohort another academic center (n = 32). Results median survival (MS) 1 13.6 months. Significant factors grading (p = 0.046), ypT- (p = 0.001), ypN- (p = 0.011) R-category (p = 0.015), lymphangiosis (p = 0.021), clinical (p = 0.004) response (p = 0.006), but localization or addition (G1/2:0 points; G3/4:1 points), (responder: 0; nonresponder: 1) (complete:0; R1:1; R2:2) defines two groups significantly different (p = 0.001) [low risk group (Score 0/1), n = 22: MS 35.3 months, 3-year-survival 47.6%); high 2/3/4) n = 126: 12.0 14.2%]. showed strong trend validation (p = 0.063) (MS reached, 57.1%); 19.9 6.7%)]. Conclusion We observed long-term after EGC. simple help identify subgroup chance resection. However, accurate estimation achieving complete resection, which an integral element score, remains challenging.